aibio
Distress ·
Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group
The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going.
COYA Coya Therapeutics, Inc.
Coya Therapeutics (COYA) news
Latest Coya Therapeutics news
We have not published a story on Coya Therapeutics yet. When there is news, it will appear here.
What Coya Therapeutics does
Coya Therapeutics is a clinical-stage biotechnology company developing therapies that enhance the function of regulatory T cells (Tregs). The company says Treg dysfunction is an important pathophysiological component of neurodegenerative, autoimmune and metabolic diseases. Its lead asset, COYA 302, is a Treg-enhancing biologic that combines the company's proprietary low dose interleukin-2 (COYA 301, or LD IL-2) with the immunomodulatory drug CTLA4-Ig. Coya is conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study of COYA 302 for amyotrophic lateral sclerosis (ALS). The FDA accepted the company's Investigational New Drug application for COYA 302 in August 2025, and the company announced dosing of ALS patients in December 2025. Coya's autologous Treg cell therapy has completed Phase 1 and Phase 2a studies in ALS. The company also describes Treg-derived exosomes as one of its three modalities. Its net loss was $21.2 million for the year ended December 31, 2025, and it had an accumulated deficit of $62.0 million at that date.
| Product or program | What it is | Stage |
|---|---|---|
| COYA 302 | Treg-enhancing biologic combining low dose IL-2 and CTLA4-Ig, for neurodegenerative disorders | Phase 2 |
| Autologous Treg cell therapy | Patient-derived regulatory T cell therapy studied in ALS | Completed Phase 1 and Phase 2a studies |
Coya Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $7.9 million | $3.6 million |
| Research and development | $16.7 million | $11.9 million |
| Net income (loss) | -$21.2 million | -$14.9 million |
| Cash from operations | -$10.7 million | -$10.3 million |
| Cash and equivalents | $46.8 million | $38.3 million |
Questions about Coya Therapeutics
What is the ticker symbol of Coya Therapeutics?
Coya Therapeutics, Inc. trades under the ticker COYA on NASDAQ.
Where is Coya Therapeutics listed?
Coya Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Coya Therapeutics?
The SEC Central Index Key (CIK) for Coya Therapeutics, Inc. is 1835022. Its filings are on SEC EDGAR.
How many shares does Coya Therapeutics have outstanding?
23,457,849 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Coya Therapeutics listed under?
Our directory records Coya Therapeutics, Inc. under United States.
What does Coya Therapeutics do?
Our directory classifies Coya Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Coya Therapeutics?
The ISIN recorded for Coya Therapeutics, Inc. is US22407B1089.
Does aibio.space cover Coya Therapeutics?
aibio.space lists Coya Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Coya Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does Coya Therapeutics develop?
Coya Therapeutics is a clinical-stage biotechnology company developing therapies that enhance the function of regulatory T cells (Tregs). The company says Treg dysfunction is an important pathophysiological component of neurodegenerative, autoimmune and metabolic diseases.
What is COYA 302 from Coya Therapeutics?
COYA 302: Treg-enhancing biologic combining low dose IL-2 and CTLA4-Ig, for neurodegenerative disorders Stage: Phase 2.
What is Autologous Treg cell therapy from Coya Therapeutics?
Autologous Treg cell therapy: Patient-derived regulatory T cell therapy studied in ALS Stage: Completed Phase 1 and Phase 2a studies.
What was Coya Therapeutics's revenue last year?
$7.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Coya Therapeutics profitable?
Coya Therapeutics, Inc. reported a net loss of $21.2 million for the fiscal year ended Dec 31, 2025, and used $10.7 million of cash in operations, per its annual report to the SEC.
How much does Coya Therapeutics spend on research and development?
$16.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Coya Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Coya Therapeutics, Inc.
- CIK
- 1835022
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- COYA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 12645 MEMORIAL DR., SUITE F1 #305, HOUSTON, TX, 77024
- Phone
- 650.739.3939
- Shares outstanding
- 23,457,849 as of 2026-08-07 (10-Q filed 2026-08-11)
Recent filings
Listing details
- Company
- Coya Therapeutics, Inc.
- Ticker
- COYA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US22407B1089
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction